T he idea of awarding patents for specific gene sequences has been a contentious subject since at least the early 1990s, when it first became technologically possible to generate such sequences in large numbers. But US courts have consistently upheld these patents. Even in Europe, where the practice is particularly controversial, gene patenting has been codified into law since 1998. For better or worse, gene patents had seemed destined to be a settled part of the intellectual-property landscape.
Until 29 March, that is, when the US District Court for the Southern District of New York shocked the biotech community by invalidating patents covering mutations in the BRCA1 and BRCA2 genes that are used to assess the risk of breast and ovarian cancer. Myriad Genetics, a company based in Salt Lake City, Utah, holds exclusive licences on these patents and has aggressively defended them. In 2009, a group of patients, researchers and clinicians sued Myriad, asserting, among other complaints, that the patents hamper medical research. And District Court judge Robert Sweet largely agreed.
Beyond the ruling's power to make headlines, industry observers and legal experts see little chance that it will pose a real threat to gene patents. Not only are US courts outside the boundaries of New York's southern district not compelled to follow Sweet's precedent, but Myriad Genetics has pledged to appeal. The case will next be heard in the Court of Appeals for the Federal Circuit in Washington DC, which many observers feel favours patent holders.
Nevertheless, the decision does reflect growing concern about the impacts of gene patents on genetic testing. As the biotech industry inches closer to the long-anticipated era of personalized medicine, genetic tests promise to exert increasing influence in the clinic. But fully realizing that promise will require a view of gene patenting that is considerably more sophisticated than the one-size-fits-all standard that now prevails.
Genetic testing is undergoing a revolution. Classic tests relying on mutations in one or two genes, such as the BRCA1 and BRCA2 tests, are giving way to complex analyses involving many genetic signatures. Tests for a genetic heart condition called long QT, for example, now assay a dozen genes. Eventually, moreover, these complex analyses will themselves give way to whole-genome sequencing. Strict enforcement of single-gene patents in this landscape could ensnare genetic tests in a patent thicket -a tangled web of patents that would have to be negotiated before a given test could be performed. Such a situation threatens to hinder innovation.
There are also legitimate concerns that gene patents can limit patient and researcher access to genetic tests. This need not always be the case: tests for mutations associated with cystic fibrosis are
Winners take all
Scientific competition is lacking in Japan, and efforts to increase it are not always best focused.
I
n a country such as Japan, where personal loyalties are strong and university pedigrees are often akin to a family bond, objective evaluation of grants can be a challenge. That is perhaps one reason why Japan has historically distributed comparatively little of its science funding through competitive grants, preferring instead to spread it more evenly by funnelling the money into the basic operating budgets of universities and research institutions. In 2009, only 13.8% of the country's reseach funding was allocated through competitive grant schemes -up from just 8.9% in 2002 -a considerably lower proportion than in the United States.
Although this approach might seem democratic and fair, Japanese patented, and the patents licensed to many companies. Those companies seem to have managed to turn a profit on the tests without creating a monopoly. But in light of these concerns, an advisory committee to the US Department of Health and Human Services recently embarked on an analysis of the impact of gene patents on genetic testing. Its report, finalized in February, distinguishes between the use of a gene patent to cover a genetic test -in which the tester simply observes the sequence of a gene -and the use of that patent to protect investment in developing biotherapeutics, when patent holders use genetic information as a platform for invention. Given this distinction and the importance of preserving access to gene tests in the clinic, the committee recommended that gene-patent rights should not be enforced when they are violated in the course of research or genetic testing. This proposal leaves many details still to be hammered out -and in any case it faces an uncertain future. Health-department secretary Kathleen Sebelius has yet to decide whether to recommend that Congress adopts the changes -and no bill has yet been introduced. But the proposal has already prompted a sharp outcry from biotechnology lobbyists and some members of Congress, who fear that it could hurt the nascent genetic-testing industry. Nevertheless, the advisory committee has provided one way forward. But whichever way they choose, Sebelius, Congress and the biotechnology industry should act without delay, implementing the basic principle of access to valuable genetic information for patients and researchers alike. officials have increasingly come to realize that it often fails in the larger test of picking the best science. During the past decade, as Japan has struggled with a stagnant economy, international patent disputes and competition from an emergent China, officials have repeatedly sought to make Japanese researchers stronger on the international scene by upping the competition at the domestic level.
Those efforts have not always paid off -for example, plans to double competitive funding between 2001 and 2005 fell short because the economy couldn't keep up and the science budget plateaued. But change may now be afoot with the massive ¥100-billion (US$1.1 billion) Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST) -a plan that was slashed by the new government last year, but that is nevertheless handing out some of the biggest competitive grants Japanese researchers have ever seen (see page 966). The 30 winning scientists will now have four years to spend an average of ¥3.3 billion each, and will enjoy much greater autonomy under this 'researcher-focused' plan than that offered by previous grant programmes.
FIRST represents an ambitious and worthwhile step for Japan. However, the programme could have been better planned. Consider, for example, that most of the 30 FIRST winners are already worldleading innovators -they include a Nobel laureate and some of the top-cited scientists in their fields. The majority of them were already the recipients of significant grants, and four have been leaders or co-leaders at one of the five World Premier International Research Centers -a 2007 initiative intended to attract top-quality scientists from around the world to work with their Japanese counterparts. These outstanding researchers have accomplished much, and will undoubtedly accomplish more. But it would have been encouraging to see some new faces. Because Japan's strategy for world-class innovation rewards researchers solely on the basis of their past success, it runs the risk of missing some excellent ideas from younger, lessestablished researchers.
It is also worth asking whether all of these projects require such huge investment. Some clearly do -one example being the Hitachi corporation's effort to develop a holographic electron microscope. This could open a new window onto atomic structures, thereby benefiting hundreds of researchers in various fields. But it is less clear whether all of the FIRST projects will be able to make such productive use of their massive budgets.
A proportion of the FIRST money might arguably have been better spent on increasing the pot of money available through the alreadyexisting mechanism for doling out small competitive grants: the 'Grants-in-Aid' programme administered by one of the country's leading research funding agencies, the Japan Society for the Promotion of Science. Such funding is crucial for small groups hoping to look into risky but potentially groundbreaking ideas -the way that many of the FIRST project leaders made the major discoveries that led them to fame. Moreover, the Grants-in-Aid programme has been forced to cut the average size of its awards in recent years, Welcome Nature Communications S ince the launch of Nature Genetics in 1992, the number of Nature research journals has grown to 16 -the most recent, Nature Chemistry, was launched a year ago. This month sees the launch of the seventeenth: Nature Communications.
All of the previous Nature research journals have focused on a particular discipline or community of research interests. Their aim is to publish the most original and scientifically impact-making research appropriate to those particular audiences. Their high ranking in the citation league tables would suggest that this goal is generally being fulfilled.
Nature Communications differs in being multidisciplinary. It aims not to compete with the established Nature journals, but to publish rigorous and comprehensive papers that represent advances of significance to specialists within each field. In addition, it welcomes submissions in fields that are not represented by a dedicated Nature research journal -for example, developmental biology, plant science, microbiology, ecology and evolution, palaeontology, astronomy and high-energy physics (see go.nature.com/xJzuY5). Readers will find in the launch issue papers on topics including classical and quantum correlations under decoherence; a candidate gene for mechano reception in Drosophila sensory cilia; a strategy to obtain sequence-regulated vinyl copolymers using metal-catalysed step-growth radical polymerization; how a ritualized vibratory signal evolved from locomotion in territorial caterpillars; and more besides.
Like all Nature journals, it is editorially independent. It is also the first Nature research journal to be funded in hybrid fashion: by both subscriptions and optional authors' fees that allow instant free access to their published papers. (It is our publishers' policy to keep subscription rates of hybrid journals under review to reflect the volume of content that is behind the subscription firewall.) Furthermore, it is the first Nature journal to be launched entirely without a print edition: its content is available only online.
Nature welcomes this distinctive new sibling publication -this time, serving the whole research community.
■ from ¥3.34 million in 2003 to ¥2.89 million in 2008, because Japan's overall research budgets have remained flat even as the country tries to support an increasing number of researchers. That surge was created, in part, by a programme launched in 1995 that successfully produced thousands of new postdocs but didn't find them jobs (see Nature 449, 1084-1085; 2007) .
These concerns aside, however, Japan's government and research community must now follow through on FIRST, giving these projects the support and participation they need to realize their full value. But the next time the government invests large sums in competitive funding, it should first make sure that the country's basic foundations for science are in good repair -and that it is truly seeking out the most creative projects. They are not always in the obvious places.
■ "The government should make sure that the country's basic foundations for science are in good repair -and that it is seeking out the most creative projects."
